Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-12-09
2000-11-21
Knode, Marian C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 245, 536 231, 435 6, A61K 3170
Patent
active
061503398
ABSTRACT:
A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. They can be composed of at least about 40% guanosine nucleotides. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4388306 (1983-06-01), Field et al.
patent: 4981957 (1991-01-01), LeBleu et al.
patent: 5075217 (1991-12-01), Weber
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5397702 (1995-03-01), Cahalan et al.
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5567604 (1996-10-01), Rando et al.
He et al., "Characterization of Human Cytomegalovirus UL84 Early Gene and Identification of Its Putative Protein Product," J. Virology, 66(2), 1098-1108 (1992).
Oram et al., "Use of Recombinant Plasmids to Investigate the Structure of the Human Cytomegalovirus Genome," J. Gen. Virology, 59, 111-129 (1982).
Weston et al., "Sequence of the Short Unique Region, Short Repeats, and art of theLong Repeats of Human Cytomegalovirus," J. Mol. Biology, 192, 177-208 (1986).
Tamashiro et al.(I), "Structure of the Heterogeneous L-S Junction Region of Human Cytomegalovirus Strain AD169 DNA," J. Virology, 52(2), 541-548 (1984).
Mocarski et al., "Structure and Variability of the a Sequence in the Genome of Human Cytomegalovirus (Towne Strain)," J. Gen. Virology, 68, 2223-2230 (1987).
Tamashiro et al.(II), "Terminal Structure and Heterogeneity in Human Cytomegalovirus Strain AD 169," J. Virology, 59(3), 591-604 (1986).
Hennighausen et al., "Nuclear Factor 1 Interacts with Five DNA Elements int eh Promoter Region of the Human Cytomegalovirus Major Immediate Early Gene," EMBO J., 5(6), 1367-1371 (1986).
Rasmussen et al., "Sequences in Human Cytomegalovirus Which Hybridize with the Avian Retrovirus Oncogene v-myc Are G+C Rich and Do Not Hybridize with the Human c-myc Gene," Molecular & Cellular Biology, 5(6), 1525-1530 (1985).
G. Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research, 5(9), 539-549 (1988).
Miller et al., "Control of Ribonucleic Acid Function by Oligonucleoside Methylphosphonates," Biochemie, 67, 769-776 (1985).
Marshall et al., "Phosphorodithioate DNA as a Potential Therapeutic Drug," Science, 259, 1564-1570 (1993).
Gura, "Antisense Has Growing Pains--Efforts to Develop Antisense Compounds for Cancer, AIDS, and Other Diseases Have Encountered Some Unexpected Questions About How the Drugs Really Work," Science, 270, 575-577 (1995).
Kreig et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," Nature, 374, 546-549 (Apr. 6, 1995).
Patick et al., "Antiviral and Resistance Studies of AG1343, an Orally Bioavailable Inhibitor of Human Immunodeficiency Virus Protease," Antimicrobial Agents and Chemotherapy, 40(2), 292-297 (Feb., 1996); supplied but not cited by applicant.
Rusconi et al., "Naphthalene Sulfonate Polymers with CD4-Blocking and Anti-Human Immunodefiency Virus Type 1 Activities," Antimicrobial Agents and Chemotherapy, 40(1), 234-236 (Jan. 1996); supplied but not cited by applicant.
Wallace et al.(I), "Pharmacokinetics and Distribution of a .sup.33 P-Labeled Anti-Human Immunodefiency Virus Oligonucleotide (AR177) After Single-and Multiple-Dose Intravenous Administration to Rats," J. Pharmacology and Experimental Therapeutics, 280(3), 1480-1488 (1997); supplied but not cited by applicant.
Wallace et al. (II), "Single-Dose Hemodynamic Toxicity and Pharmacokinetics of a Partial Phosphorothioate Anti-HIV Oligonucleotide (AR177) After Intravenous Administration to Cynomolgus Monkeys," J. Pharmacology and Experimental Terapeutics, 278(3), 1306-1312 (1996); supplied but not cited by applicant.
Wallace et al. (III), "Repeat-Dose Toxicity and Phamacokinetics of a Partial Phosphorothioate Anti-HIV Oligonucleotide (AR177) After Bolus Intravenous Administration to Cynomolgus Monkeys," J. Pharmacology and Experimental Therapeutics, 278(3), 1313-1317 (1987); supplied but not cited by applicant.
Rando, "Clinical Trial Results of Aronex's Anti-HIV Oligonucleotide (AR177) and Recent Antisense Technology Advances," IBC's Fourth International Symposium on Antisense Therapeutics with New Applications for Genomics, International Business Communications, Inc., Wyndham Emerald Plaza Hotel, San Diego, CA, Feb. 6-7, 1997; only abstract supplied; supplied but not cited by applicant.
Clinical Update, Hybridon, Inc., Worcester, MA, Feb. 10, 1997; press release apparently obtained from the Internet; supplied but not cited by applicant.
Hybridon Moves GEM.RTM. 91 into Confirmatory Clinical Trial in Advanced HIV-Positive Patient, Hybridon, Inc., Cambridge, MA, Feb. 10, 1997; original release date was Feb. 6-7, 1997 in San Diego, CA (See ref. RB supra); supplied but not cited by applicant.
Kahn et al., "Phase 1 Study of AR-177 (Zintevir), an HIV-1 Inhibitor with Significant Activity Against Integrase Protein: Safety, Pharmacokinetics, Immunologic and Virologic Activity," Abstract of presentation at the 11th International Conference on AIDS, Vancouver, BC, Jul. 7-12, 1996; supplied but not cited by applicant.
Kern, "Preclinical Evaluation of Antiviral Agents: In Vitro and Animal Model Testing," Ch. 3 in Antiviral Agents and Viral Diseases in Man, Galasso et al. (eds.), Raven Press, Ltd., New York, NY, 1990, pp. 87-114, only pp. 87 and 94-95 supplied.
Fennewald Susan
Hogan Michael E.
Ojwang Joshua O.
Rando Robert F.
Zendegui Joseph G.
Aronex Pharmaceuticals, Inc.
Crane L. Eric
Knode Marian C.
LandOfFree
Anti-viral guanosine-rich oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-viral guanosine-rich oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-viral guanosine-rich oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257247